John Timberlake has been commercializing diabetes drugs and devices for 25 years. Over the course of his career, one theme has always stood out: if you want people to use your product, it has to be made with the end-user in mind. “It’s really [about] understanding the patient first and then designing the technology around […]
Tandem Diabetes Q3 sales top The Street
Tandem Diabetes Care (NSDQ:TNDM) today posted third quarter earnings and lifted its sales guidance for the year, beating Wall Street expectations for the quarter in sales but falling behind on losses per share. The San Diego-based company posted losses of $34.2 million, or 62¢ per share, on sales of $46.3 million for the three months ended […]
Tandem wins approval for insulin pump in Canada
Tandem Diabetes Care (NSDQ:TNDM) won a medical device license from Health Canada last week for its t:slim X2 insulin pump. The device integrates directly with Dexcom‘s (NSDQ:DXCM) G5 continuous glucose monitor and is the only system of its kind approved in Canada, according to the San Diego, Calif.-based company. Tandem said it plans to launch the […]
Tandem lifts full-year sales guidance
Tandem Diabetes Care (NSDQ:TNDM) increased its full-year sales guidance, citing strong U.S. sales in the third quarter and the launch of its t:slim X2 insulin pump in international markets. The company increased its 2018 sales guidance from $140 million – $148 million to $150 million – $158 million. If Tandem posts sales within its newly-revised range, […]
Tandem launches insulin pump with predictive low glucose suspend feature in US
Tandem Diabetes Care (NSDQ:TNDM) last week launched its t:slim X2 insulin pump with Basal-IQ technology in the U.S. The company’s latest pump includes a predictive low glucose suspend feature designed to reduce the frequency and duration of hypoglycemia. Using the Basal-IQ algorithm, the system predicts where a user’s blood sugar levels are heading up to 30 […]
Tandem reels in $115m from public offering
Tandem Diabetes Care (NSDQ:TNDM) said today that it raised roughly $115 million from an underwritten public offering. The San Diego, Calif.-based company offered 3,508,770 shares of its common stock at $28.50 apiece. Underwriters fully exercised an option to buy 526,315 additional shares of common stock, Tandem noted. Also today, the company announced that results from the […]
Tandem prices $100m offering
Tandem Diabetes Care (NSDQ:TNDM) has priced an underwritten public offering of 3.5 million shares of common stock at $28.50 apiece. The San Diego, Calif.-based company expects to reel in roughly $100 million in gross proceeds from the offering. Tandem also gave underwriters a 30-day option to buy up to 526,315 additional shares of common stock. The […]
Tandem posts mixed Q2 results
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell this week after the insulin pump maker topped sales expectations but missed earnings estimates on Wall Street with its second-quarter financial results. The San Diego, Calif.-based company posted a net loss of -$59.4 million on sales of $34.1 million for the 3 months ended June 30, for sales growth of […]
Tandem wins FDA nod for insulin pump with predictive low glucose suspend feature
The FDA this week approved Tandem Diabetes Care‘s (NSDQ:TNDM) t:slim X2 insulin pump with a predictive low glucose suspend feature designed to cut the frequency and duration of hypoglycemia. The San Diego, Calif.-based company said that upon launch, its new product will also feature Dexcom‘s (NSDQ:DXCM) G6 continuous glucose monitoring system. Tandem expects that the […]
Tandem wins CE Mark for t:slim X2 insulin pump
Tandem Diabetes Care (NSDQ:TNDM) said today that its t:slim X2 insulin pump won CE Mark clearance in the European Union. The San Diego, Calif.-based company plans to start selling the device in international markets in the second half of 2018. Tandem’s latest drug-pump won FDA approval in August last year. The t:slim X2 insulin pump features […]
- 1
- 2
- 3
- …
- 5
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn